- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: MDX-1103 | MEDI-545 | MEDI545
Compound class: Antibody
Comment: Sifalimumab is a monoclonal antibody targeting interferon α1 (IFNA1), that was developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE). Development of sifalimumab was terminated and MedImmune concentrated on their alternative anti-IFNα agent anifrolumab.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Sequence BLAST using the heavy and light chain variable regions of sifalimumab provides 100% matches to sequences patented with application US7741449 . The sequence matches identify sifalimumab as clone 13H5 in the patent.
|No information available.|
|Summary of Clinical Use|
|Sifalimumab reached Phase 2 clinical trial in patients with SLE. Results from NCT01283139 were promising, and although no efficacy of safety failures were reported , development of sifalimumab was discontinued for strategic business reasons in 2015.|
|Mechanism Of Action and Pharmacodynamic Effects|
|IFNα appears to enhance the maturation or activation of dendritic cells (DCs) [7-11], and increased expression of type I interferons has been described in several autoimmune diseases including SLE [1-2,5,13] and insulin-dependent diabetes mellitus (IDDM) . The evidence validates IFNα as a drug target for the development of novel therapeutics for these diseases. Sifalimumab acts to neutralise circulating IFNα.|